FTT PET/CT in Pancreatic Neuroendocrine Tumors
Phase 1 Recruiting
12 enrolled
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1 Completed
56 enrolled 19 charts
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
GEN602
Phase 1 Unknown
127 enrolled
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
Phase 1 Completed
49 enrolled
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
Phase 1 Withdrawn
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Phase 1 Terminated
21 enrolled
Tenatumomab
Phase 1 Terminated
2 enrolled
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Phase 1 Terminated
5 enrolled
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Phase 1 Completed
22 enrolled
Spectroscopy With Surface Coils and Decoupling
Phase 1 Completed
582 enrolled
Rapamycin With Grapefruit Juice for Advanced Malignancies
Phase 1 Completed
41 enrolled
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
Phase 1 Completed
108 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Phase 1 Completed
26 enrolled